London, UK - 4 December 2016 Responding to NHS England's decision to fund a £10million trial of Pre-Exposure Prophylaxis (PrEP) for HIV in 10,000 people, Dr Chloe Orkin, Chair of the British HIV Association (BHIVA), said:

"We are hugely relieved that NHS England has decided to invest in Pre-Exposure Prophylaxis (PrEP). From early 2017, PrEP will be offered to ten thousand people as part of a £10 million trial. It is a really positive step towards making this highly effective, safe intervention available to those at the highest risk of HIV infection. After the trial, NHS England envisions a full roll out.

"We look forward to playing our part in implementing the safe delivery of PrEP. We will work with other agencies and organisations to deliver PrEP and strive to make the 17 new HIV infections that occur each day a thing of the past."

Ends
For further information or comment, please contact Mediscript:
Jacqueline English: 020 8369 5388, email: [email protected]

 

About BHIVA
Founded in 1995, BHIVA is the leading professional organisation committed to providing excellence in the care of those living with and affected by HIV. It acts as a national advisory body to professions and other organisations on all aspects of HIV care. BHIVA also provides a national platform for HIV care and contributes representatives for international, national and local committees dealing with HIV care. In addition, BHIVA works to promote undergraduate, postgraduate and continuing medical education within HIV care.     www.bhiva.org    @BritishHIVAssoc